NAMPT and NAPRT1 mutations in normal tissues and tumor samples

send to a friend share this

NAMPT and NAPRT1 mutations in normal tissues and tumor samples

Wednesday, 05.11.2014

In this work, mutations in NAMPT and NAPRT1 genes were identified in normal tissues and tumor samples. Some mutations presented different frequencies, which can be explained by the population of origin of the samples. Evaluation of the structural and functional impact of these mutations indicates that they can be relevant in a disease context.

 

Authors and Affiliations:
Sara Duarte-Pereira 1, Sarah S. Silva 1, Luísa Azevedo 1,2, Luísa Castro 3, António Amorim 1,2 & Raquel M. Silva 1,3
1 IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal;
2 Faculty of Sciences, University of Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal
3 IEETA - Institute of Electronics and Telematics Engineering of Aveiro, University of Aveiro, Santiago Campus, 3810-193 Aveiro, Portugal

 

Abstract:
Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinate phosphoribosyltransferase domain containing 1 (NAPRT1) are the main human NAD salvage enzymes. NAD regulates energy metabolism and cell signaling, and the enzymes that control NAD availability are linked to pathologies such as cancer and neurodegeneration. Here, we have screened normal and tumor samples from different tissues and populations of origin for mutations in human NAMPT and NAPRT1, and evaluated their potential pathogenicity. We have identified several novel polymorphisms and showed that NAPRT1 has a greater genetic diversity than NAMPT, where any alteration can have a greater functional impact. Some variants presented different frequencies between normal and tumor samples that were most likely related to their population of origin. The novel mutations described that affect protein structure or expression levels can be functionally relevant and should be considered in a disease context. Particularly, mutations that decrease NAPRT1 expression can predict the usefulness of Nicotinic Acid in tumor treatments with NAMPT inhibitors.

 

Journal: Scientific Reports 

 

Link: http://www.nature.com/srep/2014/140909/srep06311/full/srep06311.html